ROIV - Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study | Benzinga
Tuesday, Roivant Sciences (NASDAQ:ROIV) and Priovant Therapeutics announced results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU).
Roivant Sciences was founded by former Republican Party presidential candidate Vivek Ramaswamy.
NIU is a group of disorders characterized by intraocular inflammation at different levels of the eye.
At week 24, 29% (5/17) of subjects in the brepocitinib 45 mg arm and 44% (4/9) of subjects in the brepocitinib 15 mg arm met Treatment Failure criteria, with lower failure rates reflecting greater treatment benefit.
The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib ...